Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan in combined pre- and post-capillary pulmonary hypertension due to left ventricular dysfunction
2013-003822-96Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary hypertension (PH) and Left Heart Failure comparing Macitentan 10 mg with Placebo (2 arms). Primary endpoint: Safety and tolerability of macitentan 10 mg. Started Mar 2014; status: completed.
02
Drugs
macitentan
03
Conditions
pulmonary hypertension (PH)Left Heart Failure
Beyond the preview
Go deeper on 2013-003822-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003822-96.